BR112022006862A2 - Peptídeo, composição, e, método para tratar dor ou aumentar a sensibilidade à dor - Google Patents

Peptídeo, composição, e, método para tratar dor ou aumentar a sensibilidade à dor

Info

Publication number
BR112022006862A2
BR112022006862A2 BR112022006862A BR112022006862A BR112022006862A2 BR 112022006862 A2 BR112022006862 A2 BR 112022006862A2 BR 112022006862 A BR112022006862 A BR 112022006862A BR 112022006862 A BR112022006862 A BR 112022006862A BR 112022006862 A2 BR112022006862 A2 BR 112022006862A2
Authority
BR
Brazil
Prior art keywords
pain
peptide
composition
treat
agents
Prior art date
Application number
BR112022006862A
Other languages
English (en)
Portuguese (pt)
Inventor
Bhattacharjee Arindam
Original Assignee
Univ New York State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New York State Res Found filed Critical Univ New York State Res Found
Publication of BR112022006862A2 publication Critical patent/BR112022006862A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112022006862A 2019-10-10 2020-10-12 Peptídeo, composição, e, método para tratar dor ou aumentar a sensibilidade à dor BR112022006862A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962913512P 2019-10-10 2019-10-10
PCT/US2020/055289 WO2021072392A1 (en) 2019-10-10 2020-10-12 Analgesic and anesthetic peptides and other agents

Publications (1)

Publication Number Publication Date
BR112022006862A2 true BR112022006862A2 (pt) 2022-07-05

Family

ID=75437541

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022006862A BR112022006862A2 (pt) 2019-10-10 2020-10-12 Peptídeo, composição, e, método para tratar dor ou aumentar a sensibilidade à dor

Country Status (10)

Country Link
US (1) US20240294571A1 (https=)
EP (1) EP4051690A4 (https=)
JP (1) JP2022551467A (https=)
KR (1) KR20220079651A (https=)
CN (1) CN114829372A (https=)
AU (1) AU2020364246A1 (https=)
BR (1) BR112022006862A2 (https=)
CA (1) CA3157686A1 (https=)
IL (1) IL292102A (https=)
WO (1) WO2021072392A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025029752A2 (en) * 2023-07-28 2025-02-06 Gate Science, Inc. Methods and systems for pain management and testing thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU733719B2 (en) * 1996-10-23 2001-05-24 Trustees Of The University Of Pennsylvania, The Improved vaccines
IL136076A0 (en) * 1997-11-26 2001-05-20 Zymogenetics Inc Mammalian cytokin-like polypeptide -10
KR20030069989A (ko) * 2000-09-08 2003-08-27 다이이찌 산토리 파마 가부시키가이샤 심부전 치료제
PL2211873T3 (pl) * 2007-10-22 2013-01-31 Amorphical Ltd Stabilny amorficzny węglan wapnia wchodzący w skład fosforylowanych aminokwasów
WO2012019192A2 (en) * 2010-08-06 2012-02-09 Mount Sinai School Of Medicine Cell-permeable molecules as growth factor receptor antagonists
CN111712252A (zh) * 2017-12-13 2020-09-25 纽约州立大学研究基金会 用于治疗疼痛和提高疼痛敏感性的肽和其它药剂
CN112218650A (zh) * 2018-01-15 2021-01-12 单侧Ip私人有限公司 肽及其用途

Also Published As

Publication number Publication date
CN114829372A (zh) 2022-07-29
JP2022551467A (ja) 2022-12-09
CA3157686A1 (en) 2021-04-15
AU2020364246A1 (en) 2022-05-12
US20240294571A1 (en) 2024-09-05
KR20220079651A (ko) 2022-06-13
IL292102A (en) 2022-06-01
WO2021072392A1 (en) 2021-04-15
EP4051690A1 (en) 2022-09-07
EP4051690A4 (en) 2024-01-17

Similar Documents

Publication Publication Date Title
IN2014KN01715A (https=)
EA201491049A1 (ru) Противораковый слитый белок
MX340014B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340015B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2012009000A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340016B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2014001375A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
BR112013008407A2 (pt) antígenos de clostridium difficile
MX360208B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
IN2014KN01716A (https=)
MX363136B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
RU2015113348A (ru) Проникающие в клетки пептиды, связывающие интерферон-регулирующий фактор 5
EA201390820A1 (ru) Слитый белок против рака
EA201200515A1 (ru) Полипептиды и их применение
DE602005020165D1 (de) Verfahren zur herstellung von l-arginin, l-ornithin oder l-citrullin
CY1113115T1 (el) Πεπτιδια - αναστολεις συντηξης του ηiv με βελτιωμενες βιολογικες ιδιοτητες
BR112022005757A2 (pt) Uricase aperfeiçoada e método de tratamento de hiperuricemia usando a mesma
EA201790341A1 (ru) Анти-ск8 антитела для применения в лечении рака
MX2021014497A (es) Peptidos.
BR112022003300A2 (pt) Método para aumentar a contagem de linfócitos usando proteína de fusão de il-7 em tumores
EA201391546A1 (ru) Противораковый слитый белок
MX2017008994A (es) Formulacion de peptidos inhibidores mk2.
BR112022006862A2 (pt) Peptídeo, composição, e, método para tratar dor ou aumentar a sensibilidade à dor
EA202090802A1 (ru) Пептидная композиция для лечения повреждений, связанных с возбуждающей нейротоксичностью
BR112016021000A2 (pt) Composições e métodos para prevenir ou tratar dis-função crônica do aloenxerto de pulmão (clad) e fi-brose pulmonar idiopática (ipf)

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2854 DE 16-09-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.